Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Invitrogen teams up with Biosynth for MRSA detection products

Invitrogen teams up with Biosynth for MRSA detection products

8th November 2007

Invitrogen and Biosynth have got together to launch a fluorescence-based culture medium for the rapid detection of MRSA in hospitals and medical settings.

Biosynth, a manufacturer of specialty chemicals for the life science and pharmaceutical industries, intends to produce and sell the new BCM MRSA ELF culture media under licence from Invitrogen’s Molecular Probes business.

With current culture methods requiring 48 hours to yield results, BCM MRSA ELF is designed to provide faster test results for active surveillance culturing, the most widely used method in hospitals and clinics to monitor, manage and prevent transmission of MRSA.

"MRSA is an enormous public threat and can jeopardise the lives of tens of thousands of hospital patients each year," commented Dr Urs Spitz, chief executive of Biosynth.

Kip Miller, senior vice-president of BioDiscovery at Invitrogen, added: "The launch of this new media for MRSA detection is another example of how we are deploying our proprietary technologies to address threats to public health."

Founded in 1987, Invitrogen provides products and services supporting pharmaceutical and biotech companies worldwide, supplying essential life science technologies for disease research, drug discovery and commercial bioproduction. ADNFCR-1050-ID-18347557-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.